Merck & Company Inc (MRK)vsRecursion Pharmaceuticals Inc (RXRX)
MRK
Merck & Company Inc
$144.52
-2.23%
HEALTHCARE · Cap: $362.27B
RXRX
Recursion Pharmaceuticals Inc
$2.91
-8.79%
HEALTHCARE · Cap: $2.37B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 98648% more annual revenue ($67.38B vs $68.23M). MRK leads profitability with a 3.6% profit margin vs 0.0%. MRK earns a higher WallStSmart Score of 42/100 (D).
MRK
Hold42
out of 100
Grade: D
RXRX
Hold35
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-74.0%
Fair Value
$84.93
Current Price
$144.52
$59.59 premium
Intrinsic value data unavailable for RXRX.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Strong operational efficiency at 35.2%
Generating 5.5B in free cash flow
Revenue surging 258.5% year-over-year
Conservative balance sheet, low leverage
Reasonable price relative to book value
Areas to Watch
4.7% revenue growth
ROE of 5.5% — below average capital efficiency
3.6% margin — thin
Elevated debt levels
0.0% earnings growth
0.0% margin — thin
ROE of -54.6% — below average capital efficiency
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.
Bull Case : RXRX
The strongest argument for RXRX centers on Revenue Growth, Debt/Equity, Price/Book. Revenue growth of 258.5% demonstrates continued momentum.
Bear Case : MRK
The primary concerns for MRK are Revenue Growth, Return on Equity, Profit Margin. A P/E of 148.4x leaves little room for execution misses. Thin 3.6% margins leave little buffer for downturns.
Bear Case : RXRX
The primary concerns for RXRX are EPS Growth, Profit Margin, Return on Equity.
Key Dynamics to Monitor
MRK profiles as a value stock while RXRX is a hypergrowth play — different risk/reward profiles.
RXRX carries more volatility with a beta of 1.15 — expect wider price swings.
RXRX is growing revenue faster at 258.5% — sustainability is the question.
MRK generates stronger free cash flow (5.5B), providing more financial flexibility.
Bottom Line
MRK scores higher overall (42/100 vs 35/100). Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Recursion Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that decodes biology by integrating technological innovations in biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company is headquartered in Salt Lake City, Utah.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?